Roivant Sciences Ltd
ROIV
Company Profile
Business description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Contact
50 Broadway
7th Floor
LondonSW1H 0BD
GBRT: +44 2074003347
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
750
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.30 | 31.20 | 0.35% |
| CAC 40 | 8,027.35 | 51.23 | 0.64% |
| DAX 40 | 24,248.71 | 257.44 | 1.07% |
| Dow JONES (US) | 48,941.90 | 557.37 | -1.13% |
| FTSE 100 | 10,264.69 | 99.24 | -0.96% |
| HKSE | 25,898.61 | 197.27 | -0.76% |
| NASDAQ | 25,067.80 | 46.64 | -0.19% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,035.70 | 61.98 | -0.47% |
| S&P 500 | 7,200.75 | 29.37 | -0.41% |
| S&P/ASX 200 | 8,680.50 | 38.80 | 0.45% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |